UCB, a global biopharmaceutical company, announced that it will present 15 abstracts across its rheumatology portfolio at ACR Convergence 2022 to be held in Philadelphia, November 10–14, 2022. The abstracts, including two with late-breaking data, have been accepted as four oral presentations, eight e-posters, and three ‘Ignite Talks’ which are five-minute in-person presentations focused on the highest ranked posters at the meeting.
“The breadth of new data we are presenting at ACR Convergence 2022, including the first presentation of bimekizumab 52-week data in psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis, underscore our commitment to address unmet patient needs and to raise standards of care,” said Emmanuel Caeymaex, Executive Vice President, Immunology Solutions and Head of U.S., UCB.
UCB is investigating bimekizumab in psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS) also known as radiographic axSpA. The efficacy and safety of bimekizumab in PsA, nr-axSpA and AS have not been established, and it is not approved for use in these indications by any regulatory authority worldwide.
Bimekizumab data highlights
Data evaluating bimekizumab in the treatment of PsA and across the spectrum of axSpA will be shared across three oral presentations, three ‘Ignite Talks’ and six e-posters.
One oral presentation and one ‘Ignite Talk’ will detail late-breaking 52-week data from the bimekizumab studies. The oral presentation will present results from the Phase 3 BE OPTIMAL study evaluating bimekizumab in patients with active PsA who were biologic naïve. The ‘Ignite Talk’ will share data from the Phase 3 BE MOBILE 1 and BE MOBILE 2 studies evaluating bimekizumab in the treatment of nr-axSpA and AS, respectively.
A second oral presentation will share data from the Phase 3 BE COMPLETE study, evaluating bimekizumab in the treatment of active PsA in patients with a previous inadequate response or intolerance to Tumor Necrosis Factor Inhibitors (TNFi-IR). A third oral presentation will share 24-week data from the Phase 3 BE MOBILE 1 study evaluating bimekizumab in nr-axSpA.
In addition, 24-week data from the BE MOBILE 2 study evaluating bimekizumab in the treatment of AS and key patient reported outcomes from the Phase 3 BE MOBILE 1 and BE MOBILE 2 studies will be presented in two ‘Ignite Talks’.
CIMZIA® (certolizumab pegol) data highlights
Data evaluating certolizumab pegol in the treatment of active axSpA will also be shared across one oral presentation and two e-posters. The oral presentation will detail an exploratory analysis which aims to evaluate the relationship between objective signs of inflammation and clinical outcomes following 12 weeks of certolizumab pegol treatment in patients with active axSpA.
